Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive study
Authors:
Open Access
- 6 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 6 (3) , 203-208
Abstract
Background: Tumor-related epilepsy (TRE) is common in patients with low-grade oligodendrogliomas. TRE is difficult to control despite multiple antiepileptic drugs (AEDs) in up to 30% of patients. Chemotherapy has been used for treatment to avoid potential radiotherapy-related neurotoxicity. This study evaluates the effect of temozolomide on seizure frequency in a homogeneous group with World Health Organization (WHO) grade II oligodendrogliomas. Methods: A retrospective analysis was conducted of adult patients with WHO grade II oligodendrogliomas and TRE followed at Memorial Sloan Kettering between 2005 and 2015 who were treated with temozolomide alone either as initial treatment or for disease progression. All had seizures 3 months prior to starting temozolomide. Seizure frequency was reviewed every 2 cycles and at the end of temozolomide treatment. Seizure reduction of ≥50% compared to baseline was defined as improvement. Results: Thirty-nine individuals met inclusion criteria. Median follow-up since starting temozolomide was 6 years (0.8-13 years). Reduction in seizure frequency occurred in 35 patients (89.7%). Improvement was independent of AED regimen adjustments or prior antitumor treatment in 16 (41%); of these, AED dosage was successfully reduced or completely eliminated in 10 (25.6%). Twenty-five patients (64.1%) remained on a stable AED regimen. The majority (n = 32, 82%) had radiographically stable disease, 5 (12.8%) had objective radiographic response, and 2 (5.2%) had disease progression. Conclusions: Temozolomide may result in reduced seizure frequency, and permit discontinuation of AEDs in patients with WHO II oligodendroglioma. Improvement was observed irrespective of objective tumor response on MRI, emphasizing the importance of incorporating seizure control in assessing response to tumor-directed therapy.Keywords
Funding Information
- National Institutes of Health (P30-CA008748)
- National Institutes of Health (P30-CA008748)
This publication has 31 references indexed in Scilit:
- Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological studyNeuro-Oncology, 2011
- Predictors of seizure freedom after resection of supratentorial low-grade gliomasJournal of Neurosurgery, 2011
- Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomasJournal of Neurosurgery, 2011
- Long‐term surgical outcomes of temporal lobe epilepsy associated with low‐grade brain tumorsCancer, 2009
- Seizure characteristics and control following resection in 332 patients with low-grade gliomasJournal of Neurosurgery, 2008
- Temozolomide for low-grade gliomasNeurology, 2007
- A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with OligodendrogliomaCancer Research, 2006
- Epilepsy in low‐grade gliomas: The impact on cognitive function and quality of lifeAnnals of Neurology, 2003
- PCV Chemotherapy for Recurrent Oligodendrogliomas and OligoastrocytomasNeurosurgery, 1998
- Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resectionJournal of Neurosurgery, 1993